COLLABORATION FORMULATION HÔPITAL SPÉCIALISÉE

Arecor Therapeutics plc

("Arecor" ou le "Groupe")

ARECOR ANNOUNCES EXCLUSIVE SPECIALTY HOSPITAL FORMULATION COLLABORATION

Cambridge, Royaume-Uni, 10 novembre 2022 : Arecor Therapeutics plc (AIM : AREC), le groupe biopharmaceutique faisant progresser les thérapies d'aujourd'hui pour permettre une vie plus saine, today announces that it has signed an exclusive formulation study collaboration with the pharmaceutical division of one of the world's largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.

Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to develop a differentiated, stable, liquid drug product, for intravenous administration, that is Ready-to-Use ("RTU"). The new liquid formulation of the product supports safe medication practices and operational efficiency by eliminating the need for reconstitution.  The partner will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model to further develop and commercialise the product.  

This collaboration adds to Arecor's growing portfolio of pre-license technology partnerships which, subject to licensing, typically include both potential milestone and royalty payments and could offer significant future recurring revenue upside potential for the Group. 

Sarah Howell, chef de la direction d'Arecor, a déclaré :  "This collaboration further demonstrates the strength of our proprietary technology platform, Arestat™, and its potential in the development of Ready-to-Use medicines. This is a field in which Arecor is building a considerable portfolio of potential specialty hospital products, as well as bringing our technology and experience to further our partners' products.  Our expertise in formulating complex medicines, when combined with our partner's global network and specific local knowledge of providing access to the major markets worldwide, will be key to advancing these fast, safe and effective treatments for patients."

-FIN-

Pour plus d'information veuillez contacter:

Notes aux rédacteurs

À propos d'Arecor

Arecor Therapeutics plc est une société biopharmaceutique à vocation mondiale qui transforme les soins aux patients en mettant sur le marché des médicaments innovants grâce à l'amélioration des produits thérapeutiques existants. En postulant notre plate-forme technologique de formulation propriétaire innovante, Arestat™, nous développons un portefeuille interne de produits exclusifs dans le diabète et d'autres indications, et travaillons avec des sociétés pharmaceutiques et biotechnologiques de premier plan pour fournir des formulations améliorées de leurs produits thérapeutiques. L'Arestat™ est soutenue par un vaste portefeuille de brevets. 

Pour plus de détails, veuillez consulter notre site Web, www.arecor.com